ELEVANCE HEALTH INC (ELV) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:ELV - US0367521038 - Common Stock
349.88 USD
+6.58 (+1.92%)
349.88 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 74% to ELV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 393.94. This target is 12.59% above the current price.
ELV was analyzed by 28 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about ELV.
In the previous month the buy percentage consensus was at a similar level.
ELV was analyzed by 28 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-19 | Deutsche Bank | Downgrade | Buy -> Hold |
| 2025-12-18 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-26 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-04 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-28 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-23 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-22 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-22 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-14 | Goldman Sachs | Initiate | Neutral |
| 2025-10-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-10 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-10-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-08 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-09-05 | UBS | Maintains | Buy -> Buy |
| 2025-09-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-25 | Baird | Maintains | Neutral -> Neutral |
| 2025-07-22 | Barclays | Maintains | Overweight -> Overweight |
| 2025-07-22 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-21 | Argus Research | Downgrade | Buy -> Hold |
| 2025-07-18 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-07-18 | Guggenheim | Maintains | Buy -> Buy |
| 2025-07-18 | UBS | Maintains | Buy -> Buy |
| 2025-07-18 | Barclays | Maintains | Overweight -> Overweight |
| 2025-07-18 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-16 | Truist Securities | Maintains | Buy -> Buy |
| 2025-07-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-14 | UBS | Maintains | Buy -> Buy |
ELEVANCE HEALTH INC / ELV FAQ
What do analysts expect the price target to be for ELEVANCE HEALTH INC (ELV)?
28 analysts have analysed ELV and the average price target is 393.94 USD. This implies a price increase of 12.59% is expected in the next year compared to the current price of 349.88.
What is the consensus rating for ELV stock?
The consensus rating for ELEVANCE HEALTH INC (ELV) is 74.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.